Copeptin Associates with Cause-Specific Mortality in Patients with Impaired Renal Function: Results from the LURIC and the 4D Study
Overview
Authors
Affiliations
Background: In chronic kidney disease (CKD) arginine vasopressin (AVP) cannot efficiently act via renal V2-receptors. AVP is upregulated leading to augmented activation of V1a- and V1b-receptors, which might contribute to the increase in cardiovascular and infectious complications in CKD. Here, we evaluate copeptin, a surrogate of AVP, and its association with cause specific mortality among patients within the whole spectrum of renal function.
Methods: Copeptin was measured in baseline samples from the LURIC (n = 3131 patients with coronary angiograms) and the 4D-Study (n = 1241 type 2 diabetic hemodialysis patients). Patients were stratified into 4 groups: estimated glomerular filtration rate (eGFR) ≥90 mL/min/1.73 m, 60-89 mL/min/1.73 m, <60 mL/min/1.73 m, and hemodialysis. The association of copeptin with mortality was assessed by Cox proportional hazards regression during 9.9 years of median follow-up in the Ludwigshafen Risk and Cardiovascular Health (LURIC) study and 4 years of median follow-up in the German Diabetes Dialysis Study (4D-Study).
Results: Median copeptin increased with decreasing eGFR: 5.6 [interquartile range (IQR), 3.1-8.1] pmol/L (eGFR ≥90 mL/min/1.73 m), 6.7 (2.9-10.5) pmol/L (eGFR 60-89 mL/min/1.73 m), 15.3 (6.7-23.9) pmol/L (eGFR <60 mL/min/1.73 m), and 80.8 (51.2-122) pmol/L (hemodialysis), respectively. Per SD increase in copeptin, the risk of coronary, infectious, and all-cause mortality increased by 25, 30, and 15% [hazard ratios (HR), 1.25; 95% CI, 1.13-1.39; HR, 1.30; 95% CI, 0.98-1.71; and HR, 1.15; 95% CI, 1.05-1.25], respectively, in patients with eGFR 60-89 mL/min/1.73 m. Except for coronary death, results were similar among patients with more advanced renal disease. No significant association was found in patients with normal renal function.
Conclusions: Copeptin concentrations were independently associated with coronary, infectious, and all-cause mortality in patients with renal impairment. In patients with normal renal function no significant association was found.
Michon-Colin A, Metzger M, Bankir L, Gauci C, Brunel M, Baron S Clin Kidney J. 2023; 16(12):2472-2481.
PMID: 38046034 PMC: 10689138. DOI: 10.1093/ckj/sfad149.
Schneider M, Schmid M, Nadal J, Krane V, Saritas T, Busch M Kidney Med. 2023; 5(11):100725.
PMID: 37915964 PMC: 10616426. DOI: 10.1016/j.xkme.2023.100725.
The role of copeptin in kidney disease.
Iglesias P, Silvestre R, Fernandez-Reyes M, Diez J Endocrine. 2022; 79(3):420-429.
PMID: 36242751 DOI: 10.1007/s12020-022-03219-0.
Tong C, Li Q, Kong L, Ni X, Halengbieke A, Zhang S J Endocrinol Invest. 2022; 45(12):2233-2245.
PMID: 35896944 DOI: 10.1007/s40618-022-01848-w.
Velho G, Ragot S, El Boustany R, Saulnier P, Fraty M, Mohammedi K Cardiovasc Diabetol. 2018; 17(1):110.
PMID: 30071874 PMC: 6071392. DOI: 10.1186/s12933-018-0753-5.